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Open accAbstract Purpose: To investigate the dose–response relationship and pain-relieving effect of
radium-223, a highly bone-targeted alpha-pharmaceutical.
Methods: One hundred patients with castration-resistant prostate cancer (CRPC) and painful
bone metastases were randomized to a single intravenous dose of 5, 25, 50 or 100 kBq/kg
radium-223. The primary end-point was pain index (visual analogue scale [VAS] and analgesic
use), also used to classify patients as responders or non-responders.
Results: A signiﬁcant dose response for pain index was seen at week 2 (P = .035). At week 8
there were 40%, 63%, 56% and 71% pain responders (reduced pain and stable analgesic con-
sumption) in the 5, 25, 50 and 100 kBq/kg groups, respectively. On the daily VAS, at week 8,
pain decreased by a mean of 30, 31, 27 and 28 mm, respectively (P = .008, P = .0005,
P = .002, and P < .0001) in these responders (post-hoc analysis). There was also a signiﬁcantNCT00667199.
774384; fax: +46 8 307771.
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S. Nilsson et al. / European Journal of Cancer 48 (2012) 678–686 679improvement in the brief pain inventory functional index for all dose-groups (P = .04, .01,
.002 and .02, Wilcoxon signed rank test). Furthermore, a decrease in bone alkaline phospha-
tase in the highest dose-group was demonstrated (P = .0067). All doses were safe and well tol-
erated.
Conclusion: Pain response was seen in up to 71% of the patients with a dose response observed
2 weeks after administration. The highly tolerable side-effect proﬁle of radium-223 previously
reported was conﬁrmed.
 2012 Elsevier Ltd.Open access under CC BY-NC-ND license. 1. Introduction
Bone metastases, present in more than 90% of patients
who die from prostate carcinoma,1 may cause severe
pain,2 neurological symptoms, pathological bone frac-
tures, spinal cord compression and pancytopenia with
considerable impact on general suﬀering, reduced func-
tional capacity and increased dependency on others.3
The optimal therapy should prolong survival, provide
pain relief and decrease skeletal morbidity. Bone pain in
prostate cancer is treated with a combination of
analgesics, hormonal treatment, chemotherapy, bisphos-
phonates, external beam radiotherapy and beta-emitting
radio-pharmaceuticals. Despite these eﬀorts, many
patients experience unrelieved pain, even when taking
strong opioids.4–8 Alternative therapies with a tolerable
side-eﬀect proﬁle are needed to target bone metastases
and improve quality of life.
Alpha-pharmaceuticals deliver high linear-energy
transfer (high-LET) short-range irradiation (<100 lm),
generating localised eﬀective radiation zones with high
probability of inducing double-strand DNA breaks in
cancer cells, and lower surrounding tissue penetration
compared with beta-emitting radiopharmaceuticals.9
Radium-223 chloride (Alpharadine) is a highly bone-
targeted alpha-pharmaceutical8,10 demonstrating antitu-
mor properties in an experimental skeletal metastases
model of human breast cancer cells.11 In a phase II study,
64 prostate cancer patients with painful bone metastases
were randomised to receive external radiotherapy plus
either four doses of radium-223, 50 kBq/kg, or placebo,
at intervals of 4 weeks. Median overall survival improved
in the radium-223 group compared with placebo (65
versus 46 weeks, respectively; P = .017).12,13
This study investigated whether radium-223 could
relieve pain in a dose-related manner in patients with
castration-resistant prostate cancer (CRPC) and painful
bone metastases, whether a pain-relieving eﬀect occurs
within each dose-group, and whether pain reduction is
associated with improved functional status.
2. Patients and methods
2.1. Patients
Patients with prostate adenocarcinoma were eligible
if they were castration-resistant (hormone refractory)with testosterone levels below 50 ng/dL after orchiec-
tomy or while maintained on androgen ablation
therapy. Patients were required to have bone pain with
a score P2 on the brief pain inventory (BPI)14–17 and
evidence of progressive disease, deﬁned by prostate-
speciﬁc antigen (PSA) level increase from baseline in
two consecutive measurements at least 1 week apart
with the ﬁnal PSAP5 ng/mL. Bone scintigraphy within
6 weeks before study drug administration ascertained
multifocal osteoblastic disease and disease activity at
painful sites. The main exclusion criteria were receipt
of chemotherapy, immunotherapy, external radiother-
apy, or an investigational agent within 4 weeks, or
radiopharmaceuticals within the year before inclusion.
All patients provided written informed consent.
2.2. Study design
A double-blind, randomised, dose-ranging study
design was used to assess the eﬀect of a single injection
of 5, 25, 50 or 100 kBq/kg radium-223 in patients with
CRPC (Fig. 1).
Patients’ pre-dosing assessments included: a 1-week
diary of daily baseline pain on a 100-mm visual ana-
logue scale (VAS), recorded analgesic consumption
and complete blood count (neutrophil count P1.5 
109/L; platelet count P100  109/L; haemoglobin
>95 g/L). Radium-223 was administered as a sterile
solution of radium-223 chloride for intravenous injec-
tion. No steroids were co-administered.
Visits were scheduled at 2, 4, 8, 12 and 16 weeks after
study injection. Patients with no palliative response
8 weeks after injection could be withdrawn from the
study and treated in accordance with local practice.
Long-term safety and survival were monitored up to
2 years after dosing.
The study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice
Guidelines, and the protocol was approved by ethical,
regulatory and radiation protection boards.
2.3. Eﬃcacy and safety
The radium-223 palliative eﬀect was documented by
patient self-assessment of pain using a VAS, the BPI15
and the patient’s record of analgesic consumption. Pain
was measured using a pain index, derived from a
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Fig. 1. Study design.
Table 1
Classiﬁcation of pain index based on diary pain rating and analgesic intake.
Pain response Pain index Diary pain rating change from baseline Analgesic intake compared with baseline
Complete 1 Decrease P90% Stable or reduced
Marked 2 Decrease P50% to <90% Stable or reduced
Moderate 3 Decrease P33% to <50% Stable or reduced
Minimal 4 Decrease P20% to <33% Stable or reduced
None 5 Decrease <20% or increase <20% Stable
Pain progression 6 Increase P20% Stable or increased
Decrease <20% or increase <20% Increased
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egorised according to the World Health Organization
(WHO) analgesic ladder.17 The classiﬁcation (Table 1)
was performed by an adjudication committee before
the blind was broken. Post-hoc, patients were categorised
as pain responders (pain index score 1–4), having no
response (pain index score 5), or pain progression (pain
index score 6).
The primary eﬃcacy end-point was the pain index
from baseline to weeks 2, 4, 8, 12 and 16. Secondary eﬃ-
cacy end-points were changed from baseline in BPI pain
severity index (worst, least and average pain and pain
experienced at current time), mean and sum of items
1–4, BPI functional interference index (general activity,
mood, walking ability, work, relations with other peo-
ple, sleep and enjoyment of life), mean and sum of items
6–12, and item 5 (pain relief from medication). Overall
survival and duration of pain relief were assessed. Anal-
yses were performed on the average of VAS data
recorded over the previous 7 days, and BPI scores com-
pleted at each visit. The anticipated clinical eﬀect of a
single dose was expected to last for up to 8 weeks. Con-
sequently, statistics focused on eﬀects at week 8.
Safety end-points included adverse events (AEs),
relative change in bone-alkaline phosphatase (ALP)
and PSA, clinical laboratory tests and physical examina-
tion, all assessed at each visit. Nature and frequency ofAEs and concomitant treatment were recorded through-
out the 16-week posttreatment period.
2.4. Statistics
At the design stage, formal power calculation was not
possible. Hence, a sample size of 100 patients (25 per
dose-group) was chosen empirically. Simulations based
on diﬀerent assumptions regarding the distribution of
pain index scores indicated that this size was reasonable.
The average diary pain rating was calculated,
provided at least four VAS scores were available in a
7-day period (missing VAS values were replaced using
LOCF). No imputation was done for other missing
data. Pain relief duration was calculated by number of
consecutive days pain response criteria were met. Eﬃ-
cacy and safety data were presented using appropriate
descriptive statistics. Dose response analysis used the
Jonckheere–Terpstra test for trends in ordered end-
points and the Cochran–Armitage test for trend in
proportions with 5% signiﬁcance. A Student’s t-test
and Wilcoxon signed rank test were used for post-hoc
analysis of changes within dose-groups.
The intent-to-treat (ITT) population included all
patients who received an injection of study medication.
All statistical analyses on eﬃcacy variables used data
from patients in the per protocol (PP) population,
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with a baseline average diary pain rating P20 mm.3. Results
3.1. Patient disposition and baseline characteristics
Patients were enrolled between May 2005 and
December 2007 at 16 centres in Sweden, Germany,
France and the United Kingdom. One hundred patients
were randomized and treated (ITT population). Seven
patients were excluded from PP analysis because they
lacked an average diary pain rating of P20 mm during
the baseline period: 1, 0, 5 and 1 in the 5, 25, 50 and
100 kBq/kg groups, respectively. Seventy-eight patients
completed week 16, 32 attended the 12-month follow-
up and 8 completed the 24-month follow-up (Fig. 2).
The most common previous therapy was external
radiotherapy, received by 61 patients overall, followed
by prostatectomy in 19 patients and blood transfusion
in 16 patients. Variation was wide, with no consistent
diﬀerences between dose-groups that might confound
results. Table 2 summarises key baseline patient
characteristics.3.2. Pain index
Table 3 presents summary statistics for pain index
over time. A statistically signiﬁcant dose response
occurred at week 2. At week 8 there were 40%, 63%,
56% and 71% pain responders (pain index 64) in the
5, 25, 50 and 100 kBq/kg groups respectively (Appendix
Table A, online only), and of responders, 6/20 (30%),
8/19 (42%), 8/18 (44%) and 11/21 (52%) reached com-
plete (pain index 1) or marked pain response (pain index
2), respectively. Up to week 8, fewer patients in higher
dose-groups (50 and 100 kBq/kg) required increases inFig. 2. Disposition of all randomised patients (CONSORTanalgesia compared with lower dose-groups (Appendix
Table B, online only).
Overall at week 8, mean daily diary pain decreased,
on average, by 30 mm in the pain responder group,
did not change in the stable response group and
decreased 12 mm on average in the pain progression
group. However, this group was free to increase analge-
sic consumption.
Mean pain relief duration was 44 days in the 50 and
100 kBq/kg groups, and 28 and 35 days in the 5 and
25 kBq/kg groups, respectively. The trends in dose
response were not statistically signiﬁcant (P > .05).3.3. Brief pain inventory
TheBPI data showed similar changes to the pain severity
and functional interference indices. The Jonckheere–
Terpstra test for dose response was statistically signiﬁ-
cant at week 8 for the BPI pain severity index (P =
.040), indicating a dose-dependent treatment eﬀect at this
point.
For patients with pain response, baseline BPI pain
severity index was 4.1, 4.1, 4.9 and 3.9 in the 5, 25, 50
and 100 kBq/kg dose-groups, respectively. At week 8,
the mean score decreased by 1.6, 2.1, 1.9 and 1.8
in the same four dose-groups, respectively (P = .05,
.001, .002 and .0006, Wilcoxon signed rank test).3.4. Post-hoc analysis of pain responders
Among patients showing pain response at week 8,
baseline mean daily pain was similar across dose-groups,
between 40 and 48 mm. At week 8, pain decreased by a
mean of 30, 31, 27 and 28 mm in the 5, 25, 50 and
100 dose-groups, respectively (P = .008, P = .0005,
P = .002 and P < .0001).
Pain responders showed improvement in the BPI func-
tional interference index for all dose-groups; the mean(Consolidated Standards of Reporting Trials) diagram).
Table 2
Summary of baseline characteristics (safety population).
Parameters Statistic 5 kBq/kg 25 kBq/kg 50 kBq/kg 100 kBq/kg Total
N 26 25 25 24 100
Age (years) Mean (SD) 69.7 (6.8) 69.1 (9.2) 67.4 (6.8) 69.4 (7.3) 68.9 (7.5)
Median 72.5 70.0 67.0 71.0 70.0
Min, max 54, 81 46, 82 56, 82 58, 81 46, 82
Haemoglobin (g/L) Mean (SD) 120.4 (13.5) 119.3 (15.6) 127.3 (18.0) 121.1 (18.7) 122.0 (16.5)
Median 118.5 122.0 131.0 123.5 123.0
Min, max 96, 150 90, 142 93, 155 86, 152 86, 155
PSA (lg/L) Mean (SD) 707.3 (1245.3) 355.8 (624.4) 357.8 (724.2) 420.3 (553.4) 466.3 (848.3)
Median 228.2 138.5 157.1 129.5 148.6
Min, max 6, 5548 10, 2820 6, 3662 9, 2224 6, 5548
Platelets (109/L) Mean (SD) 272.9 (104.4) 255.6 (99.2) 256.9 (73.5) 247.7 (66.2) 258.5 (86.9)
Median 265.0 248.0 250.0 238.5 244.5
Min, max 132, 544 82, 529 108, 407 131, 390 82, 544
WBC (109/L) Mean (SD) 8.47 (3.15) 7.11 (2.61) 6.61 (1.99) 7.22 (1.82) 7.36 (2.52)
Median 8.10 6.49 6.22 7.37 6.95
Min, max 3.4, 17.5 3.2, 13.8 3.1, 9.8 3.9, 10.4 3.1, 17.5
Bone-ALP (ng/mL) Mean (SD) 163.4 (195.4) 167.4 (309.1) 166.3 (186.9) 246.7 (454.5) 184.7 (298.2)
Median 88.8 71.8 98.0 124.4 96.1
Min, max 9, 845 9, 1425 10, 828 10, 2000 9, 2000
Extent of disease (EOD) EOD 1 (<6) 2 (9%) 5 (21%) 4 (17%) 1 (4%) 12 (13%)
EOD 2 (6–20) 9 (41%) 9 (38%) 5 (21%) 8 (35%) 31 (33%)
EOD 3 (>20) 9 (41%) 9 (38%) 11 (46%) 10 (44%) 39 (42%)
EOD 4 (superscan) 2 (9%) 1 (4%) 4 (17%) 4 (17%) 11 (12%)
Time since diagnosis of
bone metastases (years)
Mean (SD) 2.17 (3.46) 2.15 (2.01) 2.53 (2.38) 2.04 (2.43) 2.22 (2.60)
Median 1.2 1.6 1.9 1.2 1.4
Min, max 0.08, 16.5 0.04, 8.6 0.26, 11.0 0.04, 8.8 0.04, 16.5
Performance status 0 7 (28%) 2 (8%) 5 (20%) 1 (4%) 15 (15%)
1 12 (48%) 16 (67%) 13 (52%) 14 (58%) 55 (56%)
2 6 (24%) 6 (25%) 7 (28%) 9 (38%) 28 (29%)
Baseline VAS Mean (SD) 41.8 (13.4) 47.7 (16.5) 41.4 (13.1) 43.4 (13.9) 43.6 (14,3)
Median 40 46 37 45 42
Min, Max 22, 85 24, 84 25, 68 23, 75 22, 85
WHO level of analgesia recorded at baseline 0 0 0 1 (4%) 0 1 (1%)
1 9 (35%) 5 (20%) 5 (20%) 2 (9%) 21 (21%)
2 6 (23%) 9 (36%) 9 (36%) 6 (26%) 30 (30%)
3 11 (42%) 11 (44%) 10 (40%) 15 (65%) 47 (48%)
Most common previous cancer medication Bicalutamide 20 (77%) 14 (56%) 14 (56%) 15 (63%) 63 (63%)
Docetaxel 8 (31%) 9 (36%) 10 (40%) 9 (38%) 36 (36%)
Leuproreline acetate 7 (27%) 7 (28%) 6 (24%) 2 (8%) 22 (22%)
Cyproterone acetate 5 (19%) 3 (12%) 6 (24%) 5 (21%) 19 (19%)
Gosereline 3 (12%) 7 (28%) 6 (24%) 2 (8%) 18 (18%)
Estramustine 5 (19%) 2 (8%) 6 (24%) 4 (17%) 17 (17%)
Abbreviations: ALP, alkaline phosphatase; PSA, prostate-speciﬁc antigen; SD, standard deviation; VAS, visual analogue scale; WBC, white blood
count; WHO, World Health Organization.
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.002, and .02, Wilcoxon signed rank test) in the 5, 25,
50 and 100 kBq/kg dose-groups, respectively.
3.5. Adverse events
Almost all (97%) patients reported at least one AE
during the study. Approximately half reported at least
one serious AE. No trend existed with increasing dose
in number, nature or seriousness of reported events
(Table 4). The most frequently reported non-haemato-logical AEs across all dose-groups were nausea, fatigue,
vomiting, diarrhoea, constipation, bone pain, urinary
tract infection and peripheral oedema. No diﬀerences
occurred between dose-groups (Appendix Table C,
online version only). The most frequent AE with an
outcome of death was disease progression.
3.6. Biomarker safety evaluations
Median per cent changes in bone-ALP are shown
in Fig. 3. Changes from baseline were statistically
Table 3
Pain index (PP population). Data presented as number of patients, mean (standard deviation) and median (minimum, maximum).
N Dose-group Jonckheere–
Terpstra test for
trends
5 kBq/kg 25 kBq/kg 50 kBq/kg 100 kBq/kg
26 24 20 23
Week
2
25
4.8 (1.4)
5.0 (2,6)
23
4.1 (1.8)
5.0 (1,6)
20
3.9 (1.4)
4.0 (1,6)
23
3.9 (1.6)
5.0 (1,6)
P = .035
Week
4
26
4.0 (1.8)
3.5 (1,6)
22
3.9 (1.9)
4.0 (1,6)
19
3.6 (1.6)
4.0 (1,6)
22
3.3 (1.8)
3.0 (1,6)
P = .123
Week
8
20
4.2 (1.8)
5.0 (1,6)
19
3.6 (2.0)
3.0 (1,6)
18
3.8 (1.9)
4.0 (1,6)
21
3.1 (1.7)
2.0 (1,6)
P = .103
Week
12
20
3.9 (2.2)
4.0 (1,6)
18
3.6 (2.3)
3.5 (1,6)
17
4.6 (1.8)
5.0 (1,6)
20
3.8 (1.8)
3.0 (2,6)
P = .717
Week
16
16
4.3 (2.1)
5.5 (1,6)
16
3.1 (2.0)
2.0 (1,6)
16
4.2 (2.0)
5.0 (1,6)
17
3.4 (2.1)
2.0 (1,6)
P = .598
Abbreviation: PP, per protocol.
Table 4
Adverse event proﬁle (safety population).
N Dose-group Overall
5 kBq/kg 25 kBq/kg 50 kBq/kg 100 kBq/kg
26 25 25 24 100
Number of patients
With at least one AE 26 23 25 23 97
With at least one related AE 13 14 14 16 57
With at least one SAE 15 16 10 8 49
With at least one AE leading to withdrawal 0 1 0 0 1
Died in 16-week post-treatment period 4 6 1 2 13
Number of adverse events
Number of AEs 166 140 135 123 564
Number of related AEs 25 29 30 44 128
Number of SAEs 33 38 14 16 101
Abbreviations: AE, adverse event; SAE, serious adverse event.
Fig. 3. Bone-alkaline phosphatase (ALP): median percentage change
from baseline (safety set).
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and 8 (P < .0001 and P = .0067, Wilcoxon signed rank
test). PSA levels increased in all dose-groups, from
baseline to week 16.
3.7. Haematological safety
Haematological events were generally mild (Table 5).
Clinical laboratory tests showed slightly greater reduc-
tions in platelet counts, white blood cell counts and
neutrophils in the two highest dose-groups. These
tended to occur in the ﬁrst 2 weeks after injection,
subsequently returning to baseline levels. The most
frequent haematological AEs (reported by >10% across
all dose-groups) were anaemia (11%) and haemoglobin
decrease (15%), with no obvious diﬀerences between
dose-groups.
Table 5
Haematological parameters: occurrence of each CTCAE grade. Safety
set; all patients/dose levels; number and percentage of patients.
Parameter CTCAE grade
0–1 2 3 4
Posttreatment period (weeks 0–16)
Haemoglobin 66 (66) 26 (26) 7 (7) 1 (1)
White blood cells 87 (87) 12 (12) 1 (1) 0
Platelets 92 (92) 2 (2) 4 (4) 2 (2)
Neutrophils 85 (90) 6 (6) 1 (1) 2 (2)
Abbreviation: CTCAE, common terminology criteria for adverse
events.
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Forty-one patients had at least one concomitant ther-
apy during the study, most commonly blood transfusion
(23 patients) and external radiotherapy (26 patients)
during the entire 16-week period; however, only ﬁve of
26 patients received external radiotherapy while still
included in the study. The other 21 of 26 patients
received external radiotherapy after they went oﬀ the
study due to pain progression (pain level 6). Of the 26
patients, only two in the 100 kBq/kg group (8%) had
external radiotherapy (compared with eight patients in
each of 5, 25 and 50 kBq/kg dose-groups).3.9. Twenty four-month safety and survival
During 24-month follow-up, no new diagnoses of
AML, MDS, aplastic anaemia or primary bone cancer
were observed across groups. At 24 months, 62 patients
had died. Median survival was 50 weeks (range:
3–110 weeks) and did not diﬀer between dose-groups.4. Discussion
This is the ﬁrst clinical study focusing on the pain-
relieving eﬀect of an alpha-pharmaceutical. Up to 71%
of these patients with metastatic CRPC had a pain
response at week 8 after a single radium-223 injection,
accompanied by signiﬁcant improvement in activities
on the BPI functional scale. The pain-relieving eﬀect
was present at 2 weeks, and mean duration in respond-
ers was approximately 50 days. The safety proﬁle was
good—only 5 transient grade 4 events.
Since radium-223 was not an “add-on” to standard
palliative care, it was considered unethical to randomise
patients with advanced CRPC and pain to placebo
control. When the trial was designed, the 5 kBq/kg
radium-223 was thought to be similar to a placebo dose;
however, it had some pain-relieving eﬀects compared to
baseline values, and occasionally this dose had a
transient mild eﬀect on neutrophils. It was therefore
not a placebo dose, although a degree of placebo
response cannot be excluded with such subjective mea-
sures as pain. However, external radiotherapy experi-
ence shows that doses needed for pain relief are
generally low.18,19 A higher dose may be required to
achieve an antitumor eﬀect; pain-relieving eﬀects
occurred in all four dose-groups, but a signiﬁcant eﬀect
on bone-ALP only with the highest dose, emphasising
the importance of distinguishing the radium-223 pain-
relieving eﬀect from its antitumor eﬀect.
In this study, radium-223 had no eﬀect on PSA levels.
This is not surprising considering only a single injection
was administered; multiple radium-223 50 kBq/kg injec-
tions have normalised PSA levels in this patient popula-
tion.12 Additionally, the eﬀect of a single radium-223injection on reducing bone-ALP observed here has also
been demonstrated with multiple injections.12 ALP nor-
malisation correlated with improved survival, indepen-
dent of PSA declines, in patients with CRPC and bone
metastases treated with docetaxel or mitoxantrone.20
Approximately 30–40% of patients in each dose-
group received prior treatment with docetaxel. Although
a low percentage versus current standards, it is consis-
tent with treatment practices of participating centers
during the study.
The pattern of analgesic use should also be consid-
ered. Reduction of regular analgesic medication would
not be expected, even with a pain decrease after
radium-223, since patients are reluctant to reduce their
analgesic medication unless it produces marked side-
eﬀects. This may explain the minority of patients across
all dose-groups reporting decreased analgesic consump-
tion. Importantly, the improvement in responders’ pain
scores was not achieved by a greater increase in analge-
sic use. The lower percentage of patients in the 100 kBq/
kg dose-group requiring external radiotherapy also sup-
ports the trend toward a more beneﬁcial eﬀect of the
highest radium-223 doses.
Even in the highest dose-group, 29% did not respond
to the single dose of radium-223. Pain continued to be a
problem in these patients despite dose escalations of opi-
oids. In fact, their pain relief was less pronounced than
that from radium-223 in responders, perhaps because of
insuﬃcient analgesic doses, suboptimal analgesic choice
or infrequent patient contact. However, the refractory
pain might also be due to diﬀerent pain mechanisms.
In external beam radiotherapy studies, the highest
attainable response is often of the magnitude of 60–
80% of patients treated. New non-clinical data indicate
that bone pain not only is nociceptive, but in early stages
has neuropathic components, partially refractory to opi-
oids.2,21 In vivo models demonstrate that sensory and
sympathetic neurons are present within the bone
marrow, mineralised bone and periosteum; sensory
ﬁbres in these tissues play a role in generating and main-
taining bone cancer pain.2,21 Indirectly, a neuropathic
component is also demonstrated in animal models, as
drugs such as gabapentin, normally used for neuro-
pathic pain, attenuate bone pain.2,21
S. Nilsson et al. / European Journal of Cancer 48 (2012) 678–686 685Pain response was seen in up to 71% of patients trea-
ted with a single dose of radium-223, with a dose
response already observed at 2 weeks and continued to
8 weeks after administration. The highly tolerable side-
eﬀect proﬁle of radium-223, previously reported, was
conﬁrmed. There was no evidence of long-term toxicity
during the 24-month follow-up. The 50 and 100 kBq/kg
doses appear to be safe, well tolerated and eﬀective, with
positive eﬀects on both pain and bone-ALP.
Drop-outs constitute a possible source of bias in the
study. The main point of evaluation was at week 8. At
that time, there were 6, 5, 4 and 2 drop-outs in the 5,
25, 50 and 100 kBq/kg dose-groups, respectively, with
more drop-outs in the lower dose-groups (6 + 5 = 11).
Since it is plausible that the drop-outs were patients
who had more pain problems, the consequence is that
the drop-out rate favoured the lower dose-groups. As
patients with more pain left the study, the mean pain
was consequently reduced.
In order to explore further the clinical potential of
radium-223 in men with CRPC and symptomatic bone
metastases, a randomised, double-blind, placebo-con-
trolled phase III survival study (ALSYMPCA (ALphar-
adin in SYMptomatic Prostate Cancer); NCT00699751)
was undertaken worldwide. In a preplanned interim
analysis, ALSYMPCA (ALpharadin in SYMptomatic
Prostate Cancer) met its primary end-point of signiﬁ-
cantly improving OS (overall survival). Based on the
recommendation of the Independent Data Monitoring
Committee, the study was stopped and patients in the
placebo group oﬀered treatment with radium-223.5. Role of the funding source
The study was sponsored and funded by Algeta ASA.
The sponsor wrote the study protocol in collaboration
with the investigators and was responsible for quality
assurance in accordance with the International Confer-
ence on Harmonisation (ICH) guideline for Good
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tigators, the sponsor made the decision to submit the
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